Literature DB >> 23266473

Specific interactions between Epac1, β-arrestin2 and PDE4D5 regulate β-adrenergic receptor subtype differential effects on cardiac hypertrophic signaling.

Magali Berthouze-Duquesnes1, Alexandre Lucas, Aude Saulière, Yuan Yan Sin, Anne-Coline Laurent, Céline Galés, George Baillie, Frank Lezoualc'h.   

Abstract

β1 and β2 adrenergic receptors (βARs) are highly homologous but fulfill distinct physiological and pathophysiological roles. Here we show that both βAR subtypes activate the cAMP-binding protein Epac1, but they differentially affect its signaling. The distinct effects of βARs on Epac1 downstream effectors, the small G proteins Rap1 and H-Ras, involve different modes of interaction of Epac1 with the scaffolding protein β-arrestin2 and the cAMP-specific phosphodiesterase (PDE) variant PDE4D5. We found that β-arrestin2 acts as a scaffold for Epac1 and is necessary for Epac1 coupling to H-Ras. Accordingly, knockdown of β-arrestin2 prevented Epac1-induced histone deacetylase 4 (HDAC4) nuclear export and cardiac myocyte hypertrophy upon β1AR activation. Moreover, Epac1 competed with PDE4D5 for interaction with β-arrestin2 following β2AR activation. Dissociation of the PDE4D5-β-arrestin2 complex allowed the recruitment of Epac1 to β2AR and induced a switch from β2AR non-hypertrophic signaling to a β1AR-like pro-hypertrophic signaling cascade. These findings have implications for understanding the molecular basis of cardiac myocyte remodeling and other cellular processes in which βAR subtypes exert opposing effects.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23266473     DOI: 10.1016/j.cellsig.2012.12.007

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  17 in total

Review 1.  Signalling in response to sub-picomolar concentrations of active compounds: Pushing the boundaries of GPCR sensitivity.

Authors:  Srgjan Civciristov; Michelle L Halls
Journal:  Br J Pharmacol       Date:  2019-04-05       Impact factor: 8.739

Review 2.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 3.  G Protein-Coupled Receptor Signaling Through β-Arrestin-Dependent Mechanisms.

Authors:  Pierre-Yves Jean-Charles; Suneet Kaur; Sudha K Shenoy
Journal:  J Cardiovasc Pharmacol       Date:  2017-09       Impact factor: 3.105

Review 4.  Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.

Authors:  Rima Kamel; Jérôme Leroy; Grégoire Vandecasteele; Rodolphe Fischmeister
Journal:  Nat Rev Cardiol       Date:  2022-09-01       Impact factor: 49.421

Review 5.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

Review 6.  A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling.

Authors:  Jihong Yang; Yufeng Liu; Xiaohui Fan; Zheng Li; Yiyu Cheng
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

Review 7.  The role of Epac in the heart.

Authors:  Takayuki Fujita; Masanari Umemura; Utako Yokoyama; Satoshi Okumura; Yoshihiro Ishikawa
Journal:  Cell Mol Life Sci       Date:  2016-08-22       Impact factor: 9.261

Review 8.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

9.  Small heat shock protein 20 (Hsp20) facilitates nuclear import of protein kinase D 1 (PKD1) during cardiac hypertrophy.

Authors:  Yuan Yan Sin; Tamara P Martin; Lauren Wills; Susan Currie; George S Baillie
Journal:  Cell Commun Signal       Date:  2015-03-07       Impact factor: 5.712

Review 10.  Exchange protein directly activated by cAMP encoded by the mammalian rapgef3 gene: Structure, function and therapeutics.

Authors:  Upasana Banerjee; Xiaodong Cheng
Journal:  Gene       Date:  2015-06-26       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.